Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Graft Versus Host Disease, Acute Clear all
Completed No phase listed Observational

A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

NCT07644351
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

NCT03699631
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

NCT02176031
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Natalizumab, Methylprednisolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 22, 2026, 3:51 PM EDT
Recruiting Phase 4 Interventional

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

NCT06982105
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis, Facial Cellulitis, Mastoiditis, Cervical Adenitis, Retropharyngeal Abscess, Peritonsillar Abscess
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

AIH for Spinal Cord Repair

NCT03780829
View directory record Official record
Conditions
SCI
Interventions
hypoxia, sham hypoxia, D-cycloserine, sham-NMDA agonist, exercise training
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
Drug · Device · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Motor-Cognitive Training

NCT06017154
View directory record Official record
Conditions
Injury;Sports
Interventions
Motor-Cognitive Training Program
Other
Lead sponsor
Ke'La H Porter
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

NCT00831766
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 22, 2026, 3:51 PM EDT
Completed No phase listed Observational

Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques

NCT02210429
View directory record Official record
Conditions
Acute Pain, Pain, Postoperative
Interventions
Elbow Fracture Fixation
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Withdrawn Not applicable Interventional

IVs With Buzzy in Chronic Pain Patients

NCT05555173
View directory record Official record
Conditions
Chronic Pain, Acute Pain
Interventions
Buzzy
Device
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional Results available

KL₄Surfactant Treatment in Patients With ARDS

NCT00215553
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
A.1 Lucinactant, B.3 SoC, A.2 Lucinactant, A.3 Lucinactant, A.4 Lucinactant, B.1 Lucinactant, B.2 Lucinactant
Drug · Other
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
16 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

NCT02979366
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
S64315 once a week, S64315 twice a week
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 22, 2026, 3:51 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Search for New Methods to Detect Acute Renal Failure

NCT00026702
View directory record Official record
Conditions
Kidney Disease, Kidney Failure, Kidney Failure, Chronic, Healthy Volunteers, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

NCT02406651
View directory record Official record
Conditions
Acute Graft vs Host Disease
Interventions
Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Duarte, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 22, 2026, 3:51 PM EDT
Recruiting No phase listed Observational

Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans

NCT06932237
View directory record Official record
Conditions
Neuro-PASC, Long COVID
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Pain Neuroscience Education for Acute and Sub-Acute Low Back Pain

NCT03722394
View directory record Official record
Conditions
Low Back Pain, Pain, Chronic, Pain, Back
Interventions
Pain Neuroscience Education
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 22, 2026, 3:51 PM EDT
Active, not recruiting No phase listed Observational

Cerebral Hemodynamics and Microemboli During Placement of Relay®Branch Thoracic Stent-Graft System

NCT05155956
View directory record Official record
Conditions
Thoracic Aortic Aneurysm, Thoracic Aortic Dissection, Microemboli
Interventions
transcranial Doppler ultrasonography (TCD)
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Results available

A Study in Depression and Associated Painful Physical Symptoms

NCT01070329
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Sherman Oaks, California • Cromwell, Connecticut • Fort Lauderdale, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 22, 2026, 3:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions
gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 22, 2026, 3:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression

NCT06088732
View directory record Official record
Conditions
Bipolar Depression
Interventions
Exercise Session, Ibuprofen 800 mg, Rest, Placebo
Other · Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 22, 2026, 3:51 PM EDT
Completed No phase listed Observational

Telestroke for Comprehensive Stroke Care in Acute Stroke Ready Hospitals

NCT03672890
View directory record Official record
Conditions
Stroke
Interventions
Telestroke
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Burnsville, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01664897
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 22, 2026, 3:51 PM EDT